logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

NSCLC: autoimmune markers predict greater anti-PD-1 benefit, AEs

Patients with preexisting antibodies had better outcomes, more irAEs than those without.